Morphocell partners with CQDM and Takeda Pharmaceuticals to advance the development of its ReLiver® technology for the treatment of liver failure
Montreal, Quebec - July 7 - Morphocell Technologies, CQDM and Takeda Pharmaceutical Company Limited, with support from the Stem Cell Network, came together to fund a $979,200 Quantum Leap project that will enable Morphocell to generate preclinical efficacy and safety data in large animals for ReLiver®ELT, a critical step to further demonstrate its potential as a life-saving treatment for acute liver failure and an important milestone to allow Morphocell to secure a Series A financing to support its journey toward a first-in-human clinical trial.
« Our investment in Morphocell is a great example of how CQDM is able to fill a funding gap for young promising companies, allowing them to generate key proof of concept data to de-risk their technology and enable future fund raisings,” said Jesse Paterson, Senior Director, Business Development at CQDM.
“This funding from CQDM and Takeda will allow us to confirm the efficacy and safety of ReLiver®ELT in a large animal model of acute liver failure. The data we will collect thanks to this investment are crucial to advance this revolutionary treatment towards the clinical phases, bringing it a step closer to the thousands of adult and children than every year suffer from severe acute liver failure” said Dr. Massimiliano Paganelli, co-founder and CEO of Morphocell Technologies and pediatric hepatologist and scientist at Centre Hospitalier Universitaire Sainte-Justine.
CQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that will accelerate the discovery and development of safer and more effective drugs. We bring together world-class pharmaceutical corporations, several Canadian biotech companies, the best scientists from both the public and private sectors, as well as the Canadian and Québec governments. CQDM’s collaborative approach bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned.
For more information - Website: www.cqdm.org, LinkedIn and Twitter.